FDA Approves Bevacizumab-maly Biosimilar for Colorectal Cancer

On Monday, April 18, 2022, the U.S. Food and Drug Administration (FDA) approved Alymsys® (bevacizumab-maly), a biosimilar to Avastin® (bevacizumab). Alymsys' approved indications include:

• Metastatic colorectal cancer in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment
• Metastatic colorectal cancer in combination with fluoropyrimidine-irinotecan- or fluoropyrimidineoxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.

Read Brand Institute's announcement for more information.

Posted 4/18/2022